Purchase Order 75N95023P00373
Award Date
6/26/23
Potential Completion Date
11/30/23
Potential Value
$35K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Dexorgen Inc.
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Gaithersburg, MD 20879, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Codex Biosolutions Inc. Research and Development Division, doing business as Codex Biosolutions Inc., has been awarded a $18,400 firm fixed-price purchase order by the National Institutes of Health's National Center for Advancing Translational Sciences to provide cell line generation services. The contract has a period of performance of September 1, 2023 through August 31, 2024 and will be performed in Gaithersburg, Maryland. No set-aside designation or subcontractors were indicated. The award...
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $25,000 firm fixed price purchase order to Codex Biosolutions Inc., located in Gaithersburg, Maryland. Codex Biosolutions will provide research and development services under the award, which runs from September 1, 2023 through August 31, 2024. As the prime contractor, Codex Biosolutions will leverage its expertise to support the National Center for...
This is a $13,200 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), to Dexorgen Inc., doing business as Codex Biosolutions Inc. The contract is for the development and optimization of antagonist assays in cells expressing different variants of the ACVR1 gene. Codex Biosolutions is a minority-owned small disadvantaged business located in Gaithersburg, Maryland that...
This is a $29,400 firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), to Dexorgen Inc., doing business as Codex Biosolutions Inc. Codex Biosolutions is a minority-owned, small disadvantaged business that specializes in advanced biotechnological research, particularly in cell line development, genetic engineering, and translational science support. The contract,...
This $18,000 firm fixed price purchase order was awarded by the National Institutes of Health's National Institute on Drug Abuse to Codex Biosolutions Inc., a minority-owned small business located in Gaithersburg, Maryland. Codex Biosolutions provides cell-based assay products and services to support research and development activities for government agencies, pharmaceutical companies, and other institutes. Under this contract, Codex is tasked with delivering specialized cell lines,...
This contract was awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences to Codex Biosolutions Inc., a minority-owned small business located in Gaithersburg, Maryland. The $18,060 firm fixed-price purchase order is for screening services to identify small molecule antagonists of the GPR17 receptor, which is involved in various diseases. Codex Biosolutions specializes in cell-based assays and has received numerous NIH contracts for research and...
This federal contract was awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Codex Biosolutions Inc., a minority-owned small business located in Gaithersburg, Maryland. The $15,100 firm fixed-price purchase order contract is for Codex Biosolutions to provide research and development services, including generating custom cell lines and supplying pseudovirus particles and stable cell lines expressing SARS-CoV-2 variants to...
This contract was awarded by the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases to Codex Biosolutions Inc., a minority-owned small disadvantaged business, to identify cellular factors that impact the production of a full-length HIV-1 envelope trimer without altering its native antigenic properties. The $599,424.00 firm-fixed-price contract is funded through the Small Business Innovation Research (SBIR) program and...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $14,844 firm fixed price purchase order to Akoya Biosciences, Inc., doing business as Phenoptics, for consumables needed to run the Codex technology as part of services offered by the CPTR Core. The order is for consumables to support the Codex single-cell analysis platform and has a completion date of January 31, 2024. No set-aside designation was applied to this award to support the...
The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a $25,770.00 firm-fixed price purchase order to Dexorgen Inc., dba Codex Biosolutions Inc., a minority-owned small business, to provide HTLV envelope protein production services. The purpose is to construct stable cell lines to increase yields of HTLV-1 envelope proteins for structural analysis and research conducted by the Vaccine Research Center (VRC). This sole-source...